Novo Nordisk's Workforce Reduction Reaches 13,000 as Company Redirects Funds to R&D
NewsData.io · United States · Sep 22, 2026
Novo Nordisk CEO Mike Maziar Doustdar confirmed the company's total workforce has shrunk by approximately 13,000 over the past year, bringing headcount to 67,000 from a peak of 78,000 in 2025. The reduction includes 9,000 layoffs from a fall 2025 restructuring plus 4,000 additional departures through attrition, unfilled roles, and voluntary exits. The cuts are intended to free up capital for R&D investment as the Danish pharma giant works to reclaim market share in the GLP-1 weight loss space from rival Eli Lilly. Staffing agencies serving biopharma clients should note continued contraction in this sector alongside selective R&D hiring investment.
Get the weekly brief by email
What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.
Related stories
Several New Jersey employers announced layoffs in early October 2026, led by Novo Nordisk (108 cuts in Plainsboro), Dr…
Eli Lilly has broken ground on a new pharmaceutical manufacturing facility in Houston, one of ten U.S…
A $500 billion wave of U.S…
BioSpace's Q2 2026 job market report shows biopharma job postings on the platform climbed 15% year over year and 12% quarter over quarter, marking the…